Cargando…

Large-cell neuroendocrine carcinoma of lung with epidermal growth factor receptor (EGFR) gene mutation and co-expression of adenocarcinoma markers: a case report and review of the literature

PURPOSE: A high rate of response to treatment with epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) has been observed in certain patients (women, of East Asian ethnicity, with non-smoking history and adenocarcinoma histology) with mutations in exons 18 to 21 of the tyrosine kina...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sakai, Yasuhiro, Yamasaki, Takashi, Kusakabe, Yoshito, Kasai, Daisuke, Kotani, Yoshikazu, Nishimura, Yoshihiro, Itoh, Tomoo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3729439/ https://www.ncbi.nlm.nih.gov/pubmed/23866929 http://dx.doi.org/10.1186/2049-6958-8-47

Ejemplares similares

Successful Erlotinib Treatment for a Patient with Gefitinib-Related Hepatotoxicity and Lung Adenocarcinoma Refractory to Intermittently Administered Gefitinib
por: Nagano, Tatsuya, et al.
Publicado: (2011)

Neuroendocrine marker staining pattern categorization of small‐sized pulmonary large cell neuroendocrine carcinoma
por: Minami, Kazuhiro, et al.
Publicado: (2019)

Pulmonary Large Cell Carcinoma Expressing Neuroendocrine Markers: The Morphological, Biological, and Neuroendocrine Features of Their Cell Lines and Surgical Cases
por: Kasai, Kiyoshi, et al.
Publicado: (1992)

Serum NSE is Early Marker of Transformed Neuroendocrine Tumor After EGFR-TKI Treatment of Lung Adenocarcinoma
por: Mao, Xiaowei, et al.
Publicado: (2022)

Spontaneous Regression of Epithelioid Angiosarcoma in a Young Woman
por: Hori, Suya, et al.
Publicado: (2017)

Epidermal Growth Factor Receptor (EGFR) Signaling Regulates Global Metabolic Pathways in EGFR-mutated Lung Adenocarcinoma
por: Makinoshima, Hideki, et al.
Publicado: (2014)

Successful osimertinib treatment for leptomeningeal carcinomatosis from lung adenocarcinoma with the T790M mutation of EGFR
por: Sakai, Hitomi, et al.
Publicado: (2017)

Composite neuroendocrine tumor and adenocarcinoma of the rectum
por: Kanno-Okada, Hiromi, et al.
Publicado: (2017)

Large cell neuroendocrine carcinoma originating from the uterine endometrium: a report on magnetic resonance features of 2 cases with very rare and aggressive tumor
por: Makihara, Natsuko, et al.
Publicado: (2012)

Histological Transformation to Large Cell Neuroendocrine Carcinoma from Lung Adenocarcinoma Harboring an EGFR Mutation: An Autopsy Case Report
por: Moriya, Rika, et al.
Publicado: (2017)

Dermatomyositis associated with prostate adenocarcinoma with neuroendocrine differentiation
por: Minagawa, Hideyuki, et al.
Publicado: (2021)

Sirt1 is a tumor promoter in lung adenocarcinoma
por: CHEN, XUE, et al.
Publicado: (2014)

EGFR mediates activation of RET in lung adenocarcinoma with neuroendocrine differentiation characterized by ASCL1 expression
por: Bhinge, Kaustubh, et al.
Publicado: (2017)

Modified ‘candy-plug’ technique for chronic type B aortic dissection with aneurysmal dilatation: a case report
por: Kotani, Sohsyu, et al.
Publicado: (2017)

BRAF V600E-mutated combined large cell neuroendocrine carcinoma and adenocarcinoma responding to targeted therapy
por: Sakamoto, Tomohiro, et al.
Publicado: (2021)

EGFR-Mutated Lung Adenocarcinoma Successfully Treated With Osimertinib After Spontaneous Transformation to SCLC and Adenocarcinoma With Neuroendocrine Differentiation: Case Report
por: Takuma, Sho, et al.
Publicado: (2021)

Pancreatic body adenocarcinoma with neuroendocrine tumor characteristics: A case report
por: TAJIMA, HIDEHIRO, et al.
Publicado: (2014)

Histological evolution from primary lung adenocarcinoma harboring EGFR mutation to high‐grade neuroendocrine carcinoma
por: Zhao, Jikai, et al.
Publicado: (2017)

Is there a role for sequential afatinib and osimertinib in patients with EGFR mutation?
por: Iwamoto, Natsuhiko, et al.
Publicado: (2022)

Epidermal growth factor receptor (EGFR)—tyrosine kinase inhibitors as a first-line treatment for postoperative recurrent and EGFR-mutated non-small-cell lung cancer
por: Moriya, Tetsuji, et al.
Publicado: (2021)

EGFR-mediated epidermal stem cell motility drives skin regeneration through COL17A1 proteolysis
por: Nanba, Daisuke, et al.
Publicado: (2021)

Unique circulating microRNAs in relation to EGFR mutation status in Japanese smoker male with lung adenocarcinoma
por: Ito, Sachio, et al.
Publicado: (2017)

Epidermal Growth Factor Receptor (EGFR) Gene Mutation Analysis in Adenocarcinoma of Lung, the First Report from Iran
por: Mohammadzadeh, Sahand, et al.
Publicado: (2019)

Mutant Proteomics of Lung Adenocarcinomas Harboring Different EGFR Mutations
por: Nishimura, Toshihide, et al.
Publicado: (2020)

A Pulmonary Large Cell Carcinoma Cell Line Expressing Neuroendocrine Cell Markers and Human Chorionic Gonadotropin α‐Subunit
por: Kasai, Kiyoshi, et al.
Publicado: (1991)

An EGFR T790M-mutated lung adenocarcinoma undergoing large-cell neuroendocrine carcinoma transformation after osimertinib therapy: a case report
por: Miyazaki, Shinichi, et al.
Publicado: (2020)

Predisposition to Lung Adenocarcinoma in a Family Harboring the Germline EGFR V843I Mutation
por: Ohtsuka, Kouki, et al.
Publicado: (2019)

Society for Translational Medicine consensus (2019 edition) shows an option for postoperative management of EGFR-mutant lung cancer
por: Nagano, Tatsuya, et al.
Publicado: (2020)

Concomitant Pulmonary Tuberculosis Impair Survival in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Lung Adenocarcinoma Patients Receiving EGFR-Tyrosine Kinase Inhibitor
por: Xie, Yalin, et al.
Publicado: (2021)

Multiple lung cancers including squamous cell carcinoma with strong PD-L1 expression and adenocarcinoma with EGFR exon 19 deletion: A case report
por: Tokuyasu, Hirokazu, et al.
Publicado: (2019)

A case of neuroendocrine carcinoma in the hepatic hilar lymph nodes concomitant with an adenocarcinoma of the gallbladder
por: Okada, Haruka, et al.
Publicado: (2016)

Pulmonary large cell neuroendocrine carcinoma with adrenal oligorecurrence successfully treated by adrenalectomy
por: Sato, Hiroki, et al.
Publicado: (2020)

Expression of Vascular Endothelial Growth Factor and Epidermal Growth Factor Receptor in Pancreatic Ductal Adenocarcinomas, Neuroendocrine Tumours and Chronic Pancreatitis
por: Angelescu, Radu, et al.
Publicado: (2013)

Prognostic implications of immunohistochemistry markers for EGFR-TKI therapy in Chinese patients with advanced lung adenocarcinoma harboring EGFR mutations
por: Zhang, Ruiguang, et al.
Publicado: (2016)

Expression of the epidermal growth factor receptor (EGFR) and the phosphorylated EGFR in invasive breast carcinomas
por: Magkou, Christina, et al.
Publicado: (2008)

First‐line epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor alone or with whole‐brain radiotherapy for brain metastases in patients with EGFR‐mutated lung adenocarcinoma
por: Chen, Yongshun, et al.
Publicado: (2016)

Involvement of SNX1 in regulating EGFR endocytosis in a gefitinib-resistant NSCLC cell lines
por: Nishimura, Yukio, et al.
Publicado: (2019)

Combined tubular adenocarcinoma, neuroendocrine carcinoma and adenocarcinoma with enteroblastic differentiation arising in Barrett esophagus
por: Sugawara, Kotaro, et al.
Publicado: (2023)

REMARRY and PURSUIT trials: liquid biopsy-guided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancer
por: Nakajima, Hiromichi, et al.
Publicado: (2021)

The prognostic significance of tumor epidermal growth factor receptor (EGFR) expression change after neoadjuvant chemoradiation in patients with rectal adenocarcinoma
por: Richter, Igor, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_iubiq3j7pd8ff2r0hrjgqiucci